Literature DB >> 16154441

Variations in plasma apolipoprotein C-III levels are strong correlates of the triglyceride response to a high-monounsaturated fatty acid diet and a high-carbohydrate diet.

W Roodly Archer1, Sophie Desroches, Benoît Lamarche, Olivier Dériaz, Nancy Landry, Bénédicte Fontaine-Bisson, Jean Bergeron, Patrick Couture, Nathalie Bergeron.   

Abstract

The objective of this study was to examine how a diet rich in carbohydrates (high-CHO) vs a diet rich in monounsaturated fatty acids (high MUFA) consumed ad libitum modulated plasma apolipoprotein C-III (apo C-III) levels and to examine the extent to which diet-induced changes in plasma apo C-III were associated with concurrent variations in plasma triglyceride (TG) levels. Forty-seven men (mean age, 35.7 +/- 11.4 years; body mass index, 29.0 +/- 5.1 kg/m2) were randomly assigned to either a high-CHO diet (CHO, 58%; fat, 26%; n = 23) or a high-MUFA diet (CHO, 45%; fat, 40%; MUFA, 22.5%; n = 24), which they consumed for 6 to 7 weeks. Fasting and postprandial lipemia after an oral fat load and fasting plasma apo C-III were measured at the beginning and at the end of the dietary intervention. Ad libitum consumption of the high-CHO diet induced a significant reduction in body weight (-2.6%, P < .0001), but had no impact on plasma apo C-III concentrations and on fasting and postprandial plasma TG levels. In contrast, ad libitum consumption of the high-MUFA diet also resulted in a significant reduction in body weight (-2.3%, P < .01) as well as in significant reductions in plasma apo C-III (-11%, P = .05) and fasting plasma TG (-17%, P < .01). Diet-induced variations in plasma apo C-III concentrations were correlated with changes in fasting and postprandial TG levels both in the high-CHO (r > 0.70, P < .001) and the high-MUFA groups (r > 0.42, P < .05). These results indicate that variations in plasma apo C-III levels are strong correlates of the fasting and postprandial plasma TG responses to high-MUFA and high-CHO diets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16154441     DOI: 10.1016/j.metabol.2005.05.004

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

Review 1.  Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.

Authors:  Marja-Riitta Taskinen; Chris J Packard; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2019-05-20       Impact factor: 5.113

2.  Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.

Authors:  Julius L Katzmann; Christian M Werner; Tatjana Stojakovic; Winfried März; Hubert Scharnagl; Ulrich Laufs
Journal:  Lipids Health Dis       Date:  2020-05-30       Impact factor: 3.876

3.  Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men.

Authors:  N Faghihnia; L M Mangravite; S Chiu; N Bergeron; R M Krauss
Journal:  Eur J Clin Nutr       Date:  2012-09-05       Impact factor: 4.016

Review 4.  The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.

Authors:  Jan Borén; Chris J Packard; Marja-Riitta Taskinen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-28       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.